203882
CR8, (S)-Isomer
2-(S)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurine, (S)-CR8
For general questions please contact our Customer Service:
Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Phone: +49 6151 72-0
Fax: +49 6151 72 2000
15 February 2012
loading
A cell-permeable (R)-DRF053 (Cat. No. 219494) analog that acts as an ATP-binding pocket-targeting CDK/CK1 dual-specific inhibitor (IC50 = 0.15, 0.080, 0.060, 0.12, 0.11, and 0.61 µM against CDK1/B, CDK2/A, CDK2/E, CDK5/p25, CDK9/T, and CK1δ/ε, respectively). Although (S)-CR8 displays in general similar kinase inhibitory profile as its (R)-enantiomer (Cat. No. 203881), it does exhibit more enhanced and reduced activity against, respectively, Dyrk1A (IC50 = 0.9 µM) and GSK-3α/β (IC50 ≥ 30 µM). Both (R)- and (S)-CR8 are much more effective than (R)-Roscovitine (Cat. Nos. 550360 and 550364) in apoptosis induction in cell cultures.
| Product information | |||
|---|---|---|---|
| Form | Off-white solid | ||
| Molar mass | 431.5 | ||
| Protect from Light | Yes | ||
| Packaged under inert gas | Yes | ||
| Purity | ≥97% by HPLC | ||
| Solubility | DMSO or EtOH | ||
| Chemical formula | C24H29N7O | ||
| CAS number | 1084893-56-0 | ||
| Store and ship information | |||
|---|---|---|---|
| Storage | +2°C to +8°C | ||
| Ship |
Ambient Temperature Only
Standard Handling |
||
